Maldonado Fabien, Limper Andrew H, Lim Kaiser G, Aubrey Marie-Christine
Division of Pulmonary and Critical Care Medicine, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Mayo Clin Proc. 2007 Jun;82(6):771-3.
Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.
替莫唑胺是一种口服烷化剂，最近被批准用于治疗多形性胶质母细胞瘤。它具有良好的副作用特征，通常耐受性良好。虽然已经描述了轻微的呼吸道症状，但需要停药的肺部毒性很少见。据我们所知，这是首例与替莫唑胺相关的机化性肺炎病例。
